France to become first EU nation to cover weight-loss meds

France became the first EU country to reimburse weight-loss medications, including GLP-1 drugs from Novo Nordisk and Eli Lilly, with coverage limited to patients with severe obesity, Health Minister Stéphanie Rist said. The policy announcement boosted market sentiment for manufacturers (related tickers shown up ~3.2% for NVO and ~4.7% for LLY in the article’s table) and could presage wider uptake and reimbursement in other European markets, supporting sales and valuation for GLP-1 producers. The move is a government policy decision with likely positive sectoral implications for pharmaceutical and healthcare names exposed to obesity drugs, and a potential catalyst for further price and volume momentum in those stocks.